Multiple Myeloma

Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy. In particular, the approval of novel and first-in-class drugs such as thalidomide, bo...

Full description

Bibliographic Details
Other Authors: Moehler, Thomas (Editor), Goldschmidt, Hartmut (Editor)
Format: eBook
Language:English
Published: Berlin, Heidelberg Springer Berlin Heidelberg 2011, 2011
Edition:1st ed. 2011
Series:Recent Results in Cancer Research
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
LEADER 02537nmm a2200313 u 4500
001 EB000380959
003 EBX01000000000000000234011
005 00000000000000.0
007 cr|||||||||||||||||||||
008 130626 ||| eng
020 |a 9783540857723 
100 1 |a Moehler, Thomas  |e [editor] 
245 0 0 |a Multiple Myeloma  |h Elektronische Ressource  |c edited by Thomas Moehler, Hartmut Goldschmidt 
250 |a 1st ed. 2011 
260 |a Berlin, Heidelberg  |b Springer Berlin Heidelberg  |c 2011, 2011 
300 |a XXIV, 340 p  |b online resource 
505 0 |a History and epidemiology -- Pathophysiology: Molecular biology of plasma cell disorders. Alterations in microenvironment -- Clinical Features: Imaging. Integrated innovative approach for diagnosis and staging -- Therapy: High-dose chemotherapy and ABSCT -- Allogeneic transplantation. Novel Drugs -- Immunotherapeutic approaches -- First-line treatment and maintenance -- Relapse -- Radiotherapy -- Kyphoplasty -- Supportive Therapy -- Appendix: Staging and prognosis systems 
653 |a Hematology 
653 |a Cancer 
653 |a Cancer Biology 
653 |a Oncology 
700 1 |a Goldschmidt, Hartmut  |e [editor] 
041 0 7 |a eng  |2 ISO 639-2 
989 |b Springer  |a Springer eBooks 2005- 
490 0 |a Recent Results in Cancer Research 
028 5 0 |a 10.1007/978-3-540-85772-3 
856 4 0 |u https://doi.org/10.1007/978-3-540-85772-3?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 616,994 
520 |a Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy. In particular, the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide means that multiple myeloma now stands at the forefront of advances in oncology drug development. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life